Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational TreatmentAccesswire · Oct 15, 2026
Dermata Therapeutics Announces Commercial Launch of Tome Foundational TreatmentAccesswire · Aug 25, 2026
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial LaunchAccesswire · Aug 21, 2026
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq RulesAccesswire · Aug 17, 2026
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026Accesswire · Aug 11, 2026
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational TreatmentAccesswire · Aug 5, 2026Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.55 | -$0.74 | Miss |
| May 13, 2026 | -$0.53 | -$0.48 | Beat |
| Mar 26, 2026 | -$1.54 | -$1.52 | Beat |
| Nov 14, 2025 | -$1.59 | -$1.65 | Miss |
| Aug 13, 2025 | -$2.90 | -$1.66 | Beat |
| May 14, 2025 | -$4.50 | -$4.50 | Beat |